Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$4.24 -5.1%	$3.58	$1.89 ▼ $5.82	$1.27B	0.64	6.46 million shs	6.64 million shs
CDTX Cidara Therapeutics	$62.90 -0.6%	$41.88	$10.14 ▼ $66.94	$1.27B	1.18	646,574 shs	302,038 shs
GPCR Structure Therapeutics	$17.59 -1.2%	$20.43	$13.22 ▼ $45.37	$1.01B	-1.89	728,968 shs	571,199 shs
VOR Vor Biopharma	$2.10 +1.4%	$1.22	$0.13 ▼ $3.29	$262.42M	2.04	8.21 million shs	2.45 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-5.15%	-17.03%	+13.07%	+75.93%	+30.06%
CDTX Cidara Therapeutics	-0.65%	+1.70%	+31.40%	+190.00%	+383.85%
GPCR Structure Therapeutics	-1.18%	-1.95%	-13.94%	-35.07%	-52.96%
VOR Vor Biopharma	+1.45%	-4.55%	+44.83%	+217.51%	+126.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.4233 of 5 stars	3.5	1.0	0.0	3.1	3.3	0.0
CDTX Cidara Therapeutics	2.8836 of 5 stars	2.6	2.0	4.6	0.6	1.7	0.0
GPCR Structure Therapeutics	2.051 of 5 stars	3.5	1.0	0.0	2.2	1.7	0.6
VOR Vor Biopharma	3.281 of 5 stars	4.3	0.0	0.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	3.00	Buy	$8.75	106.37% Upside
CDTX Cidara Therapeutics	3.11	Buy	$57.29	-8.93% Downside
GPCR Structure Therapeutics	3.00	Buy	$76.17	333.01% Upside
VOR Vor Biopharma	2.60	Moderate Buy	$5.63	168.03% Upside

Current Analyst Ratings Breakdown

Latest VOR, ABCL, CDTX, and GPCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
7/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$69.00
7/7/2025	ABCL AbCellera Biologics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	ABCL AbCellera Biologics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
6/30/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$59.00
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$35.00 ➝ $75.00
6/24/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$50.00 ➝ $68.00
6/23/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $53.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	43.89	N/A	N/A	$3.58 per share	1.18
CDTX Cidara Therapeutics	$1.27M	998.48	N/A	N/A	$14.92 per share	4.22
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	$15.10 per share	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.56	N/A	N/A	N/A	-737.56%	-15.98%	-12.38%	8/7/2025 (Estimated)
CDTX Cidara Therapeutics	-$169.83M	-$29.47	N/A	N/A	N/A	N/A	-73.04%	-54.28%	8/7/2025 (Estimated)
GPCR Structure Therapeutics	-$122.53M	-$0.87	N/A	N/A	N/A	N/A	-16.35%	-15.71%	8/6/2025 (Estimated)
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest VOR, ABCL, CDTX, and GPCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GPCR Structure Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ABCL AbCellera Biologics	-$0.17	N/A	N/A	N/A	$7.55 million	N/A
8/7/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/8/2025	Q1 2025	GPCR Structure Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
GPCR Structure Therapeutics	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	10.15	10.15
CDTX Cidara Therapeutics	N/A	3.87	3.87
GPCR Structure Therapeutics	N/A	23.29	23.29
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
CDTX Cidara Therapeutics	35.82%
GPCR Structure Therapeutics	91.78%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
CDTX Cidara Therapeutics	3.89%
GPCR Structure Therapeutics	9.43%
VOR Vor Biopharma	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
CDTX Cidara Therapeutics	90	20.16 million	19.38 million	No Data
GPCR Structure Therapeutics	136	57.34 million	51.94 million	Optionable
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable

VOR, ABCL, CDTX, and GPCR Headlines

Recent News About These Companies

Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $5.63

August 2 at 2:21 AM | americanbankingnews.com

Vor Biopharma (NYSE:VOR) Trading Down 2.9% - Time to Sell?

July 30 at 2:57 AM | marketbeat.com

Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 30 at 2:45 AM | marketbeat.com

Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

July 29, 2025 | insidermonkey.com

Vor Biopharma Announces Key Leadership Changes

July 25, 2025 | theglobeandmail.com

Vor Biopharma Inc.'s (NASDAQ:VOR) top holders are insiders and they are likely disappointed by the recent 14% drop

July 23, 2025 | finance.yahoo.com

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

July 21, 2025 | globenewswire.com

H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target

July 20, 2025 | msn.com

Vor Bio Grants Stock Options and RSUs to New Chief Development Officer Dr. Qing Zuraw

July 18, 2025 | quiverquant.comQ

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 | globenewswire.com

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

July 17, 2025 | globenewswire.com

Vor Biopharma Names Sandy Mahatme Chief Financial Officer

July 11, 2025 | marketwatch.com

Vor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 11, 2025 | finanznachrichten.de

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 10, 2025 | globenewswire.com

Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants

July 8, 2025 | seekingalpha.com

Biopharma layoffs for first half of the year jump 32% YOY

July 8, 2025 | fiercebiotech.comF

Vor Biopharma Target of Unusually High Options Trading (NYSE:VOR)

July 8, 2025 | marketbeat.com

Boston’s biotech sector reels due to Trump health policy uncertainty

July 6, 2025 | ft.com

Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 5, 2025 | marketbeat.com

Vor Biopharma Q2 EPS Estimate Decreased by HC Wainwright

July 2, 2025 | marketbeat.com

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out
By Thomas Hughes | July 16, 2025
View This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out
3 Reasons Palo Alto Networks Is Becoming a Wall Street Favorite
By Nathan Reiff | July 22, 2025
View 3 Reasons Palo Alto Networks Is Becoming a Wall Street Favorite
Sizzling Insider Buys for Your High-Yield Watchlist
By Thomas Hughes | July 8, 2025
View Sizzling Insider Buys for Your High-Yield Watchlist
Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]
By MarketBeat Staff | July 29, 2025
View Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]

VOR, ABCL, CDTX, and GPCR Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$4.24 -0.23 (-5.15%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.23 -0.01 (-0.21%)

As of 08/1/2025 08:00 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Cidara Therapeutics NASDAQ:CDTX

$62.90 -0.41 (-0.65%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$60.00 -2.90 (-4.61%)

As of 08/1/2025 06:14 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Structure Therapeutics NASDAQ:GPCR

$17.59 -0.21 (-1.18%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$17.60 +0.02 (+0.09%)

As of 08/1/2025 04:32 PM Eastern

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Vor Biopharma NYSE:VOR

$2.10 +0.03 (+1.45%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.04 -0.06 (-2.86%)

As of 08/1/2025 07:37 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time